目的对结肠癌细胞株与患者组织间的药物靶点蛋白表达进行一致性研究,以明确两者的相符性。方法检索Human Protein Atlas数据库中FDA批准的药物靶点蛋白,并对兼有患者结肠癌组织和细胞株数据的蛋白进行表达评分。通过计算蛋白在细胞株与患者间表达的一致率,总体评价两者蛋白表达的相符情况,继而采用生物信息学方法进行蛋白生物学功能和信号通路注释,评价个体患者与细胞株间蛋白表达的差异性。结果共检索得兼有细胞株(均为Caco-2细胞)和患者表达数据的药物靶点蛋白176个。患者与细胞株表达一致的蛋白比率为57.4%,与患者年龄、性别、肿瘤部位等均无相关性。两者间表达一致性较高或较低的蛋白数分别为69和82,其中47和36个蛋白表达完全一致或完全不一致。不一致蛋白在恶性肿瘤相关通路、免疫相关通路、胞外基质受体相互作用、细胞骨架与形态相关通路的富集更为显著。结论药物靶点蛋白在Caco-2细胞株与患者结肠癌组织间的表达存在一定的差异性,提示考察细胞株与患者间靶蛋白表达的一致性具有重要意义。
To study the anticancer activity of griffithin from Streptocaulon griffithii Hook.f. and its effect on apoptosis of cancer cells in vitro, the inhibitory effect of griffithin on cell proliferation was studied by MTT assay, the cell apoptosis was observed by AO/EB double decoration assay and flow cytometry. Griffithin exhibited high anticancer activity on four human cancer cell lines, with IC_ 50 ranged from 0.17-0.43 μg·mL -1 . Griffithin also induced apoptosis of PC-3 cells. Griffithin had anticancer activity and induced apoptosis of cancer cells.